TRPA1 activity inhibitor

Patent metadata

Field	Value
Publication number	US-11464720-B2
Application number	US-201816495663-A
Country	US
Kind code	B2
Filing date	Mar 13, 2018
Priority date	Mar 30, 2017
Publication date	Oct 11, 2022
Grant date	Oct 11, 2022

Abstract

This TRPA1 activity inhibitor contains a compound represented by formula (I) wherein R1, R2, R3 and R4 each independently represent a hydrogen atom or a methyl group, and R5, R6, R7 and R8 each independently represent a hydrogen atom, a methyl group or —O—R9—OH (in the formula, R9 represents an alkylene group optionally having a substituent group), provided that at least one group of R5, R6, R7 and R8 is —O—R9—OH.

First claim

The invention claimed is:

1. A composition, comprising a TRPA1 agonist and a therapeutically effective amount for inhibiting TRPA1 activity induced by the TRPA1 agonist of a compound represented by formula (I):

wherein each of R 1 , R 2 , R 3 and R 4 is independently a hydrogen atom or a methyl group, each of R 5 , R 6 , R 7 and R 8 is independently a hydrogen atom, a methyl group or a group represented by formula (II):
—O—R 9 —OH  (II)

wherein R 9 is an alkylene group which may have a substituent;
with the proviso that at least one group of R 5 , R 6 , R 7 and R 8 is a group represented by the formula (II), and
wherein the therapeutically effective amount of the compound represented by the formula (I) is able to inhibit the TRPA1 activity induced by the TRPA1 agonist.

2. The composition according to claim 1 , wherein R 9 is an alkylene group having 1 to 6 carbons which may have a substituent, in the group represented by the formula (II).

3. The composition according to claim 1 , which comprises a compound represented by formula (III):

4. A method for inhibiting TRPA1 activity, comprising a step of applying a compound in a presence of a TRPA1 agonist to a skin which needs the inhibition of the TRPA1 activity induced by the TRPA1 agonist, thereby contacting a TRPA1 -expressing cell in the skin with the compound, wherein the compound is represented by formula (I):

wherein each of R 1 , R 2 , R 3 and R 4 is independently hydrogen atom or methyl group, each of R 5 , R 6 , R 7 and R 8 is independently a hydrogen atom, a methyl group or a group represented by formula (II):
—O—R 9 —OH  (II)

wherein R 9 is an alkylene group which may have a substituent;
with the proviso that at least one group of R 5 , R 6 , R 7 and R 8 is a group represented by the formula (II), and
wherein the TRPA1 activity is exhibited by binding the TRPA1 agonist to TRPA1, thereby activating the TRPA1.

5. The method for inhibiting TRPA1 activity according to claim 4 , wherein R 9 is an alkylene group having 1 to 6 carbons which may have a substituent, in the group represented by the formula (II).

6. The method for inhibiting TRPA1 activity according to claim 4 , wherein the compound represented by the formula (I) is a compound represented by formula (III):

7. An external preparation containing a component for activating TRPA1, comprising the composition according to claim 1 .

8. An irritative sensation-mitigating agent for mitigating irritative sensation caused by TRPA1 activation, which comprises the composition according to claim 1 .

Assignees

• Mandom Corp
• Takasago Perfumery Co Ltd

Inventors

• Takaishi Masayuki
• Fujita Fumitaka
• Shimizu Hironori
• SAKUYAMA Shu
• Ishida Kenya
• Maruyama Kenji

Classifications

• A61K8/34 Primary

  Alcohols · CPC title

• A61K31/085

  having an ether linkage to aromatic ring nuclear carbon · CPC title

• A61Q5/00

  Preparations for care of the hair · CPC title

• A61K2800/75

  Anti-irritant · CPC title

• C07C43/196

  containing hydroxy or O-metal groups · CPC title